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Abstract
Elucidating the molecular drivers of human breast cancers requires a strategy capable of 
integrating multiple forms of data and an ability to interpret the functional consequences of a 
given genetic aberration. Here we present an integrated genomic strategy based on the use of gene 
expression signatures of oncogenic pathway activity (n=52) as a framework to analyze DNA copy 
number alterations in combination with data from a genome-wide RNAi screen. We identify 
specific DNA amplifications, and importantly, essential genes within these amplicons representing 
key genetic drivers, including known and novel regulators of oncogenesis. The genes identified 
include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, 
EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative 
luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective. 
Our results demonstrate that this general strategy has the potential to identify putative therapeutic 
targets within amplicons through an integrated use of genetic, genomic, and genome-wide RNAi 
data sets.
Tumorigenesis is driven by a combination of inherited and acquired genetic alterations 
resulting in a complex and heterogeneous disease. The ability to dissect this heterogeneity is 
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critical to understand the relevance of these alterations for disease phenotypes but also to 
enable the development of rational therapeutic strategies that can match the characteristics 
of the individual patient’s tumor. Many studies, including reports from The Cancer Genome 
Atlas (TCGA) project, have made use of the power of multi-platform genomic analyses to 
identify known and novel genetic drivers of tumor phenotypes1–3. This has led to the 
identification of disease subgroups with distinct characteristics and in some instances, 
distinct genetic mechanisms of disease1,2,4. The strength of this approach relies on the 
integration of large-scale genomic data to reveal biological co-variation that cannot be 
identified when using a single technology. A weakness of this approach is in the 
interpretation of the underlying biology, which generally represents an inference about 
pathway activity based upon prior knowledge concerning an individual gene mutation/
alteration.
Altered signaling pathway activity is an important determinant of the biology of a tumor and 
may predict therapeutic response; therefore, identifying mechanisms driving key 
tumorigenic pathways is essential to understand the transformation process2,5–8. To take 
advantage of the vast amounts of existing genomic data, we utilized a series of 
experimentally derived gene expression signatures capable of measuring oncogene or tumor 
suppressor pathway activity, aspects of the tumor microenvironment, and other tumor 
characteristics including proliferation rate, as a framework by which to integrate multiple 
forms of genomic data. Our results identify patterns of oncogenic signaling within each of 
the molecular subtypes of breast cancer, many of which directly correlate with DNA copy 
number aberrations. By further analyzing functional data from a genome-wide RNAi 
screen9, we identified genes essential for cell viability in a pathway-dependent, and in some 
cases, a subtype-dependent manner. Our results identify a small number of DNA 
amplifications as potential drivers of proliferation in poor outcome luminal/ER+ breast 
cancers, and in general terms, we outline an approach that could be applied to many other 
tumor types where multi-platform genomic data exist.
RESULTS
Subtype-specific patterns of oncogenic signaling
To objectively identify genetic drivers of breast cancer, we examined genomic-based 
patterns of oncogenic pathway activity, the tumor microenvironment, and other important 
features in human breast tumors using a panel of 52 previously published gene expression 
signatures (Supplementary Tables 1 and 2)10–32. Each signature was applied to the breast 
cancer gene expression microarray data (n=476) from the TCGA project (Supplementary 
Table 3) for which the molecular intrinsic subtype had been determined2. Consistent patterns 
of pathway activity emerged for each subtype, as illustrated in Figure 1A, and quantitatively 
assessed by an ANOVA test followed by a Tukey test for pair-wise comparison (Figure 1B, 
Supplementary Table 4). Analyzing differences across subtypes based on these 52 features 
demonstrated that the strongest correlation between samples existed within each molecular 
subtype (Supplementary Figure 1).
Patterns of pathway activity recapitulated known characteristics of each subtype, including 
dysregulation of pathways that can be linked to female Hormone Receptors (HR), and/or 
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oncogenes, and/or tumor suppressor mutation status (Figure 1). For example, basal-like 
tumors, which represent ~80% of triple negative breast cancers, are characterized by low HR 
signaling, mutant p53 signaling and high expression of proliferation pathway activity 
(Figure 1). Likewise, HER2-enriched (HER2E) tumors show high expression of the Her211 
and Her2- Amplicon (Amp)12 signatures, while LumA tumors show high HR signaling and 
wild-type p53 signaling. Highly proliferative LumB tumors, which also show some HR 
signaling, are distinguished from less proliferative LumA samples by increased 
proliferation-associated pathways. Thus these data robustly recapitulate many previously 
published pathways versus subtype associations.
A Pearson correlation to assess the concordance between each of the 52 signatures 
(Supplementary Figure 2, Supplementary Table 5) identified strong relationships between 
independent signatures for a given pathway as well as between related pathways. For 
example, two Myc signatures11,15,32 demonstrate an R value of 0.72, while a PIK3CA18 and 
PTEN-deleted27 signatures had a R value of 0.82. Signatures scoring different pathways 
were also concordant; for instance, Myc-mediated regulation of E2F signaling33 was 
identified by the association between the RB-LOH16 and Myc15 signatures (R=0.79), while 
EGFR-mediated activation of Stat3 signaling34 was recapitulated by the EGFR11,32 and 
Stat311,32 (R=0.72) signatures. These results provide a measure of validity for each signature 
but, since differences do exist between signatures for a specific pathway, suggest that each 
provides an opportunity to investigate a particular pathway taking into account the genetic 
manipulation used to develop a given signature.
Characterization of pathway-specific copy number alterations
We next utilized DNA copy number data from the TCGA project (n=476) to identify Copy 
Number Alterations (CNA) associated with pathway activity (Figure 2A). We first identified 
genes for which CNAs were positively (or inversely) correlated with pathway activity using 
a Spearman Rank correlation (Bonferroni corrected to control the family-wise error rate) to 
assess the relationship between pathway score and gene-level DNA segment score 
(Supplementary Figure 3, Supplementary Tables 6–57). Secondly, we used a Fisher’s exact 
test (Bonferroni corrected) to calculate the frequency of CNA gains (including high-level 
amplification and gains) or losses (including loss of heterozygosity and deletions) in 
samples with high (top quartile) pathway activity compared to all other samples (low 
activity)(Supplementary Figure 4, Supplementary Tables 6–57). To reduce potential false-
positive results associated with either strategy alone, for each signature we focused on those 
genes that were significant in both analyses (Figure 2A); potential drivers of pathway 
activity had a positive correlation and a higher amplification frequency in samples with high 
pathway activity, while potential repressors had a negative correlation and increased 
frequency of copy number losses. Mapping genes that met these criteria to chromosomal 
loci identified pathway-specific patterns of CNA (Figure 2B). Consistent with previous 
studies reporting that basal-like tumors have a higher incidence and larger spectrum of 
CNAs2,35, pathways associated with basal-like tumors have more complex patterns of CNA 
when compared to luminal-associated pathways.
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To further assess the validity of this strategy, we investigated the relationship between 
pathway activity and a chromosomal alteration of known causative activity. We first focused 
on the Her2-Amp signature12 since this signature is comprised of genes located at the 17q 
loci and since ERBB2/17q amplification is the dominant driver of this pathway. As 
illustrated in Figure 2C (Supplementary Table 27) ERBB2 is amplified in 84.9% of samples 
with high (top quartile) pathway activity compared to 7.3% of low scoring samples (q= 1.1 
× 10−55); likewise this relationship has a positive Spearman rank correlation (q= 2.4× 
10−108). While several other alterations, including MYC amplification (q=1.1× 10−02, 
q=6.3× 10−03) were also associated with this signature, thus identifying a previously known 
relationship36, ERBB2 /17q amplification was the dominant alteration identified thus 
providing a robust positive control for this strategy. As expected, similar results were 
observed when analyzing the Her2 pathway using the independently developed Her211,32 
signature (Supplementary Table 26).
This strategy was further validated by assessing the relationship between CNA and 
pathways associated with a more complex genomic landscape. Previous studies from our 
group suggest that the Her1-C213 signature predominantly measures the RAS/RAF/MEK 
arm of the EGFR pathway13. Consistent with this observation, we detected a correlation 
between the Her1-C2 signature (q<0.01) and GRB2, SOS1, KRAS, BRAF, PIK3CA, PIK3CB, 
and MYC genomic DNA amplifications as well as a negative correlation (q<0.01) with loss 
of NF1 and PI3K repressors INPP4B and PTEN (Figure 2D, Supplementary Table 24). 
Finally, we analyzed CNA associated with the RB-LOH16 signature (Figure 2E, 
Supplementary Table 47) and identified associations between it and CNA of known RB/E2F 
components including loss of RB1 and gains of E2F1 and/or E2F3. Consistent with the role 
of the RB/E2F pathway in mediating cell cycle progression and proliferation37, CCND2, 
CCND3, and MYC amplification also correlated with this signature. Collectively these 
results demonstrate that this strategy is able to link CNA with pathway activity and does so 
by focusing on all aspects of the pathway, often beyond the dominant regulator, potentially 
allowing for the identification of novel regulatory components.
Identification of amplified genes linked to pathway activity
Given the ability of this strategy to identify known CNA of pathway activity, we next used 
this approach to identify novel drivers of pathway activity. Because highly proliferative 
luminal/ER+ tumors have a poor prognosis and poor responses to existing therapies38,39, we 
sought to identify amplified genes/CNA associated with our previously published 11-gene 
PAM50 Proliferation signature with the hope that these might represent targetable drivers of 
oncogenesis.
To identify those genes that are specifically altered in highly proliferative luminal tumors, 
while excluding those genes that are associated with proliferation irrespective of subtype, 
analyses were performed on two subsets of samples: all tumors and all non-basal-like tumors 
(henceforth called luminal tumors). Some rationale for this binary distinction comes from 
recent TCGA studies where 12 tumor types were studied simultaneously and showed that 
breast tumors formed two groups, namely Basal-like and all other breast tumors (called 
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Luminal and including HER2+ tumors), suggesting that breast cancer might broadly be 
considered two main disease types40.
Examining the TCGA breast cancer dataset using the PAM50 Proliferation signature31, 
Basal-like, LumB, and HER2E tumors were found to have the highest proliferation levels 
(Figures 3A and 3B) with the top quartile (Figure 3C) comprised of Basal-like (49.6%), 
LumB (33.6%) and HER2E (16.8%) patients, whereas the top quartile of proliferative 
luminal tumors (Figure 3D) contained LumB (68.0%) and HER2E (32.0%) patients. Using 
the PAM50 Proliferation signature, we examined the frequency of CNA gains and losses in 
highly proliferative (top quartile) tumors relative to less proliferative samples irrespective of 
subtype using the previously discussed statistical strategies (Figure 3E–F, Supplementary 
Table 43). To identify those genes that are specifically amplified in highly proliferative 
luminal breast cancer, these analyses were repeated using the luminal tumor subset (Figures 
3G–H, Supplementary Table 58). Analyzing both populations of patients identified three 
classes of proliferation-associated regions (q<0.05): (1) CNAs associated irrespective of 
subtype, (2) those altered in basal-like tumors, and (3) those altered in highly proliferative 
luminal tumors. These results allowed us to focus our analyses on those genes within regions 
that were uniquely altered in highly proliferative luminal tumors by censoring proliferation-
associated genes altered in basal-like breast cancer (e.g.TP53 or INPP4B loss), or that were 
altered irrespective of molecular subtype (e.g. RB1 loss or MYC amplification). These 
analyses identified a number of regions including 3p25, 5p15, 11q13, 17q22, and 20q11-13 
that were uniquely amplified in highly proliferative luminal tumors.
Identification of pathway-specific essential genes
To distinguish essential from non-essential genes in amplified regions associated with 
proliferation in luminal tumors, we next examined data from a genome-wide RNAi screen of 
multiple breast tumor-derived cell lines9. The 52 gene expression signatures were applied to 
a panel (GSE12777)41 of breast cancer cell lines (Supplementary Figure 5, Supplementary 
Table 59), of which 27 had both mRNA expression data and were part of a RNAi 
proliferation screen in which a genome-wide shRNA library (~16,000 genes) was used to 
identify essential genes (Figure 4A)9. For each signature, a negative Spearman rank 
correlation was used to identify pathway-specific essential genes (Figure 4B, Supplementary 
Table 60) by comparing the pathway score against the normalized shRNA score across the 
panel of 27 cell lines. These analyses identified inverse relationships between the abundance 
of shRNAs targeting key regulatory genes and pathway scores. For instance, examining the 
ER11,32, Her211,32, or Stat142 signatures as controls (Figures 4C–4E) showed a negative 
correlation between pathway score and shRNA against ESR1 (p=0.0143), ERBB2 
(p=0.0227), and STAT1 (p=0.0049) or JAK3 (p=0.00013), respectively. These associations 
were expected for the ER and Her2 pathways given the relationship between HER2 or ERα 
mRNA and/or protein expression and the response of cell lines or tumors to trastuzumab or 
anti-estrogen therapies, respectively. These results confirm that this approach is able to 
identify essential genes known to be functionally associated with pathway activity, thereby 
suggesting that these data can serve as a biological filter to distinguish pathway-specific 
essential from non-essential genes.
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Amplified essential genes linked to luminal tumor proliferation
We next sought to distinguish between essential and non-essential genes within regions 
specifically amplified in highly proliferative luminal tumors. For each subset of tumors we 
identified genes in amplified regions that were positively correlated with proliferation and 
showed an increased amplification frequency (q<0.05). We next examined the RNAi data in 
all breast cancer cell lines (Supplementary Figure 6A) and in luminal/HER2+ cell lines 
(Supplementary Figure 6B) in the context of the PAM50 Proliferation signature 
(Supplementary Table 61). Comparing the results of these four analyses (Figure 5A) 
identified 19 genes that were uniquely essential for cell viability in luminal cell lines and 
that were amplified in highly proliferative luminal tumors (Figure 5B). Two additional 
genes, DNAJC5 and SNX21, were identified by RNAi analysis but were initially overlooked 
in the CNA analyses since they were located at the cusp of two segmented regions; however, 
since genes overlapping both 5’ and 3’ of these genes were amplified, these were included 
for further investigation. Of these 21 candidate genes, twelve showed a significant 
relationship between DNA copy number levels and mRNA expression in luminal tumors 
(Supplementary Figure 7). Interestingly, half of these genes were located at 20q11-13 
(EIF2S2, EIF6, SLC2A10, SNX21, ZBTB46 and DNAJC5), with two located at 3p25.1 
(FGD5 and METTL6), and the remaining genes located at 5p15 (TRIO), 11q13 (CPT1A), 
12q13 (DTX3), and 17q22-23 (MRPS23). In contrast, permuting the data labels 1000 times 
for each analysis, in all samples and in luminal samples alone, identified no gene that met 
this statistical threshold, suggesting that the 21 candidate genes could not have been 
identified by chance alone.
Validation of identified candidate genes
We next confirmed that the majority of the identified genes were significantly amplified in 
highly proliferative luminal breast tumors by analyzing an independent breast tumor dataset 
(METABRIC, n=1,992) for which both mRNA expression and genomic DNA CNA data 
were available3. Of the twelve identified genes, nine (FGD5, METTL6, TRIO, CPT1A, 
DTX3, MRPS23, EIFS2S, EIF6, and SLC2A10) were present on both platforms used in the 
METABRIC study. Each of these genes (Supplementary Figure 8) showed a significant 
relationship between CNA status and mRNA expression in luminal breast tumors (n=1,333). 
Importantly, eight of the nine, the exception being TRIO, also showed an increased 
amplification frequency in highly proliferative (top quartile) luminal tumors (Supplementary 
Figure 9), thus recapitulating one of our main findings.
To confirm that DNA mutations of genes associated with proliferation in luminal tumors did 
not confound these results, we examined the relationship between the 11-gene Proliferation 
score and the mutation frequency of the previously identified 35 significantly mutated genes 
in human breast cancers reported by TCGA2. Using a Fisher’s exact test (Bonferroni 
corrected), we determined that only TP53 (q=7.0×10−10) and MAP3K1 (q=5.0×10−03) 
mutations occurred at significantly different frequencies in highly proliferative (top quartile) 
luminal tumors compared to all other samples; TP53 mutations occurred more frequently 
(51.6% vs. 18.6%) while MAP3K1 (2.1% vs.12.4%) mutations occurred less frequently in 
highly proliferative luminal tumors (Supplementary Table 62). Moreover, we found no 
significant relationship between MAP3K1 or TP53 mutation status (Bonferroni corrected 
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Fisher’s exact test, q>0.05) and the amplification status of each candidate gene 
(Supplementary Table 63) in highly proliferative luminal tumors.
Lastly, we investigated whether expression of the candidate genes, independent of CNA 
status, was associated with proliferation in luminal breast tumors. By comparing the mRNA 
expression patterns of each candidate gene in highly proliferative luminal tumor samples 
(top quartile) against all other samples, we found that tumors lacking CNA of each candidate 
gene fell into three categories: those that exhibited a positive relationship between mRNA 
expression and the PAM50 proliferation signature (EIF2S2, EIF6, CPT1A, and MRPS23), 
those that were anti-correlated with the signature (DTX3), and those that showed no 
correlation (FGD5, METTL6, and SLC2A10) between datasets (Supplementary Figure 10). 
These data suggest that amplification is a key mechanism driving the expression of these 
genes. However, our data also suggest, not surprisingly, that for some genes overall high 
expression may be the driver, which can be accomplished by amplification or through other 
unknown means.
Candidate gene amplification correlates with poor prognosis
Previous studies have shown that highly proliferative luminal tumors have a poor 
prognosis38,39, therefore we investigated what impact amplification of each candidate gene 
had on overall survival. From the TCGA (n=388)2 and METABRIC (n=1,333)3 datasets we 
extracted the subset of LumA, LumB, or HER2E patients for which survival data was 
available (Supplementary Tables 64–65). We first analyzed data from the TCGA (Figure 
6A–E), and despite the relatively short follow-up (median: 1.7 years), determined that 
amplification of FGD5 (P<0.0001, HR: 8.0), METTL6 (P=0.0003, HR: 5.9), DTX3 
(P=0.0387, HR: 2.6), and MRPS23 (P=0.0078, HR: 2.9) predicted a significantly worse 
outcome in luminal breast cancer patients whereas CPT1A amplification had no effect on 
patient survival (P=0.3738). Extending these analyses to the METABRIC dataset (Figures 
6F–J), which has a longer median survival time (7.2 years), confirmed that FGD5 
(P=0.0170, HR: 2.0), METTL6 (P=0.0081, HR: 2.1), DTX3 (P=0.0098, HR: 1.8), and 
MRPS23 (P=0.0020, HR: 1.5) amplification correlated with a poor prognosis, while gain of 
CPT1A had no effect (P=0.099) on luminal breast cancer survival. The remaining three 
genes, showed no consistent effect on prognosis (Supplementary Figure 11). While it is 
possibly that other genes within these chromosomal loci are also prognostic, these amplified 
genes were associated with proliferation in vivo, were prognostic in multiple patient cohorts, 
and essential for cell viability in vitro.
Likewise, we determined that for most of the identified candidate genes that failed to meet 
all our predetermined criteria, amplification alone, without a coordinate increase in mRNA 
expression, was not sufficient to affect prognosis since only one (TMEM117) of these genes 
showed a consistently poor prognosis in the TCGA and METABRIC datasets 
(Supplementary Table 66). Lastly, we investigated whether the 12 initial candidate genes 
were predictive of a poor prognosis when compared with standard prognostic markers 
including molecular subtype, tumor stage, node status, ER status, HER2 status, age at 
diagnosis, and the 11-gene proliferation score when tested using a multivariate analysis (Cox 
model). We determined that amplification of a single candidate gene did not consistently 
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outperformed or improve the prognostic capacity of these clinical and genomic variables 
(Supplementary Table 67). However, these candidate genes were not identified to be 
prognostic markers, especially given that they correlate with proliferation, but instead were 
selected to be likely drivers of proliferation, a highly important prognostic feature.
DISCUSSION
Numerous studies, including many focused on human breast cancer, have made use of large-
scale analyses to investigate the genomic landscape of human cancers and to identify 
molecular heterogeneity within tumor types not previously recognized2,3,6,11. The challenge 
presented by these studies, and by the enormous amount of genomic data available from 
resources such as the TCGA and METABRIC projects, is how to integrate multiple forms of 
genomic data to investigate the biology of the disease, and how to interpret the significance 
of identified genomic alterations without relying on inferences of “known” biology to 
determine the role that these alterations play in tumorigenesis.
In this study, we utilize gene expression signatures of signaling pathways to identify patterns 
that can distinguish the known subtypes of breast cancer. These signatures are largely 
developed from controlled manipulations of the relevant pathways in vitro, and are thus 
based on experimental evidence for pathway activation as opposed to extrapolations of 
pathway activity achieved from analyses of annotated gene lists. Therefore, use of an 
experimentally derived pathway signature, as opposed to the analysis of a single genomic 
alteration, provides a measure of pathway activity irrespective of how the pathway may have 
been activated. For instance, a given pathway can be active in a subset of tumors, either as a 
result of an activating alteration (i.e. E2F1 or E2F3 amplification) or an independent event 
that inactivates a negative regulator of the pathway (i.e. RB1 loss and/or mutation), which 
nevertheless achieves the same end result (i.e. DNA replication and cell proliferation); 
importantly, we identified these four genetic events as being statistically associated with the 
RB-LOH signature16, which is dominated by E2F-regulated genes and is a strong indicator 
of cell proliferation and prognosis.
Proliferation is one of the most powerful prognostic features in breast cancers, especially for 
ER+ cancers38,39. Since proliferation is so important, we utilized a gene expression 
signature of proliferation as a means to integrate the DNA copy number data, along with 
data from a genome-wide RNAi screen of luminal breast cancer cell lines, to identify 
luminal-specific genetic drivers of proliferation. We identified 12 genes that were uniquely 
amplified in highly proliferative luminal tumors in the TCGA dataset, have a correlation 
between mRNA expression and DNA copy number, and were shown to be essential for 
luminal breast cancer cell line viability; eight were validated using the independent 
METABRIC dataset. While FGD5, METTL6, DTX3, and MRPS23 amplification was 
prognostic in luminal patients, these and many of the other identified genes have been 
previously reported to regulate tumorigenic characteristics, albeit not necessarily in human 
breast cancer. For example, FGD5 has been shown to regulate the pro-angiogenic function 
of VEGF 43, potentially leading to increased proliferation. DTX3 purportedly promotes 
Notch signaling44,45, while EIF6 is a Notch-dependent regulator of cell invasion and 
migration46 and its inhibition restricts lymphomagenesis and tumor progression47. MRPS23 
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expression is associated with proliferation, oxidative phosphorylation, invasiveness, and 
tumor size in uterine cervical cancer48. METTL6 has been reported to contribute to cytotoxic 
chemotherapy sensitivity in lung cancers49.
Several previous studies have identified chromosomal regions specifically altered in subsets 
of breast cancer, including 3p25 (encompassing METTL6, FGD5)2 and 11q13 (CPT1A)3 in 
luminal breast tumors; however these studies neither discriminated between essential and 
non-essential genes within a specific amplicon, nor did they identified the functional 
consequence of these alterations. In contrast, we have shown that these regions are uniquely 
amplified in highly proliferative luminal tumors and importantly, we distinguish between 
amplified genes that are essential for cell proliferation and thus likely contribute to 
tumorigenesis, versus those that are amplified but not essential. For instance SRC 
(20q12-13), which is co-amplified with EIF6, is similarly amplified in a significant 
percentage of highly proliferative luminal tumors (Supplementary Tables 43 and 58), but 
was not identified as essential in highly proliferative luminal breast cancer cell lines in the 
RNAi screen (Supplementary Table 60). Interestingly, in addition to its role in regulating 
translation50 and Notch signaling46, EIF6 has been reported to link Integrin-β4 to the 
intermediate filament cytoskeleton51, potentially leading to down-stream activation of SRC 
signaling. These results may explain some of the paradoxical findings of SRC in that it may 
contribute to proliferation status, but may not be essential, whereas a gene very near it, also 
linked to proliferation, is essential for cell viability in vitro. Clearly additional experiments 
are needed to address this issue, but these results highlight the complex nature, and 
importance, of this specific amplicon.
A significant challenge to translating these findings into the clinic is the identification of 
genes within amplicons that are therapeutically targetable. One such event may be 
amplification of 11q13-14/CPT1A, which was recently reported3 to be a defining feature of 
a high-risk ER+ subgroup (Integrative Cluster 2) and correlates with a poor prognosis in 
esophageal squamous cell carcinoma52. We identified CPT1A as the only gene within the 
amplified 11q13 locus required for cell viability within the confines of the proliferation 
signature and luminal cell lines, suggesting that repression of CPT1A could affect the 
proliferative phenotype of these tumors. Consistent with this hypothesis, it was recently 
reported that RNAi-mediated down-regulation, or drug-mediated inhibition of CPT1A, 
inhibited cancer cell line proliferation, migration and metastasis53–55, albeit not in breast 
cancer cell lines. Lastly, a specific inhibitor of CPT1A (ST-1326) repressed tumor formation 
and proliferation in an Eμ-myc mouse model of Burkett’s lymphoma55.
Collectively these data demonstrate the ability of this across-platforms genomics approach 
to identify novel oncogenes amplified in a subset of highly proliferative luminal breast 
cancer patients which are essential for cell viability. These data suggest that not only are 
these identified genes potential drivers of oncogenesis and that an emphasis should be 
placed on elucidating their role in breast tumorigenesis, but also that they, or their associated 
pathways, may serve as novel therapeutic targets in a subset of human breast cancers for 
which limited therapeutic opportunities currently exist.
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Agilent custom 244K whole genome gene expression microarray data for human breast 
cancer samples was acquired from The Cancer Genome Atlas (TCGA) project2 data portal. 
Samples were filtered to include only those 476 samples for which Affymetrix SNP 6.0 data 
was present. As previously described, (TCGA) data were median centered for each gene. 
Illumina HT-29 v3 expression data for the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) project (n=1,992 samples) was acquired from the 
European Genome-phenome Archive at the European Bioinformatics Institute and data were 
median centered for each gene3. Expression data for a panel of 51 breast cancer cell lines 
was acquired from GEO (GSE12777)41. Affymetrix U133+2 data were MAS5.0 normalized 
using Affymetrix Expression Console (ver1.2.1.20), and log2 transformed. Expression 
probes were collapsed using the median gene value with the GenePattern56 module 
CollapseProbes.
Affymetrix SNP 6.0 data
DNA copy number values were determined in 490 TCGA primary breast tumors (of which 
476 had matched mRNA expression data) and 1,992 METABRIC primary breast tumors 
using Affymetrix 6.0 SNP arrays as previous described2,3. Copy number segmentation and 
segment calls (i.e. NEUT, AMP, GAIN, HOMD or HETD) was performed using the 
Circular Binary Segmentation (CBS) algorithm as previously described2,3. Using the hg19 
build annotation from the UCSC genome browser, genes were selected if they fell 
completely within a CBS identified copy number segment. Genes that were not found 
completely within a copy number segment across any sample were filtered out. In the 
METABRIC dataset, the copy number call gene-matrix was determined from genes that fell 
completely within a CBS identified copy number segment. Out of the 12 genes of interest, 
SNX21, ZBTB46, and DNAJC5 were not found completely within a CBS identified segment 
among the METABRIC samples and were excluded from further analyses.
Gene expression signatures
A panel of 52 previous published gene expression signatures was used to examine patterns 
of pathway activity and/or microenvironmental states (Supplementary Table 1). In order to 
implement each signature, the methods detailed in the original studies were followed as 
closely as possible. The 22 signatures from Gatza et al.10,11,32 were originally developed 
based on a Bayesian binary regression strategy and identified a signature comprised of 
Affymetrix probe sets with positive and negative regression weights; to translate these 
signatures to a form that could be applied to non-Affymetrix expression data, the original 
reported signatures were altered. For each signature, we excluded those probe sets with a 
negative correlation coefficient. The remaining probe sets with a positive coefficient were 
then translated to the gene level, and replicate genes were merged. To apply a given 
signature to a new dataset, the expression data was filtered to contain only those genes that 
met the previous criteria and the mean expression value was calculated using all genes 
within a given signature that were present in more than 80% of samples. The list of genes in 
each modified signature is reported in Supplementary Table 2 and the scores for the TCGA 
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dataset (Supplementary Table 3) and cell line dataset are provided (Supplementary Table 
59).
Statistical analyses of signature scores
To quantify differences in patterns of signature scores across subtypes, an ANOVA followed 
by a Tukey’s post-test for pairwise comparisons was used (as shown in Figure 1B). To 
investigate the level of concordance between each of the 52 signatures, the pathway scores 
calculated for each sample in the TCGA dataset (Supplementary Table 3) were analyzed. 
The R values calculated by a Pearson correlation are reported in Supplementary Figure 2 
and Supplementary Table 5.
Identification of point mutations as a function of pathway activity
To compare the frequency of mutations, the 35 genes identified as being significantly 
mutated in human breast cancer2 were assessed in the context of the 11-gene PAM50 
Proliferation signature31. A Fisher’s exact test (Bonferroni corrected) was used to compare 
the frequency of mutations in samples with high (top quartile) and low (all other samples) in 
LumA, LumB and HER2E (n=388) samples. The frequency of mutations associated with 
each group for each signature is summarized in Supplementary Table 60–61.
Identification of copy number alterations as a function of pathway activity
To identify copy number alterations two analysis methods were independently used. A 
Spearman rank correlation, both positive and negative, was used to compare gene-level 
segment scores with predicted pathway activity. To compare the frequency of amplification 
and losses, a Fisher’s exact test was used to compare the frequency of either gene-specific 
copy number gains and amplification or deletions (both loss of heterozygosity of deletion) 
against non-amplified or non-deleted samples. Samples in the top quartile of calculated 
pathway activity were compared to those in the bottom three quartiles. For each analysis, the 
negative log10 Bonferroni-adjusted P-values are reported (Supplementary Figure 3 and 
Supplementary Figure 4). To identify genes that were significant across both methods, a 
threshold of q<0.01 (Bonferroni corrected) was set for validation (Figure 2) and q<0.05 for 
discovery (Figure 5). The Bonferroni corrected p-values for the positive and negative 
Spearman rank correlation for each gene and each signature are reported in Supplementary 
Tables 6 through 57. The frequency of copy number gains in the top quartile versus all other 
samples, as well as the Bonferroni corrected p-values calculated by a Fisher’s exact test, are 
reported for each gene and each signature (Supplementary Tables 6–57).
Analysis of genome-wide RNAi proliferation data
In order to identify genes required for cell viability in a signature dependent manner, data 
from a previously published genome-wide RNAi screen carried out on a panel breast cancer 
cell lines were analyzed9. The Gene Active Ranking Profile (GARP)-normalized data were 
obtained from the COLT database and filtered to include only those 27 cell lines for which 
gene expression data (GSE12777) were also available (acquired February 2013). To identify 
gene essential for pathway-dependent cell proliferation, a negative Spearman correlation 
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was performed comparing predicted pathway activity and GARP score for each sample. A 
threshold of p<0.05 was considered significant for all analyses.
Analysis of mRNA expression in copy number neutral samples
To assess mRNA expression in luminal tumors lacking CNA of each candidate genes, 
luminal and HER2E samples from the TCGA (n=388) and METABRIC (n=1,333) studies 
were grouping to high (top quartile) and low (all other samples). Samples with copy number 
gains (including high-level amplification or gain) or losses (both loss of heterozygosity and 
homozygous deletion) were excluded and a t-test was used to examine statistical differences 
between the expression levels of genes in each cohort.
Survival analyses
To investigate the effect that candidate gene amplification has on disease-specific survival, 
clinical data for the 1,992 patients in the METABRIC study were obtained3. The 11-gene 
PAM50 Proliferation signature31 was applied to all 1,992 samples by calculating the median 
value of the signature, for each sample. For survival analyses, patients that died of causes 
unrelated to breast cancer and patients without a date of death were censored. We extracted 
patients classified as Luminal A, Luminal B or HER2E for which survival data was reported 
(n=1,333). For survival analysis of the TCGA dataset2, we extracted patients classified as 
LumA, LumB or HER2E for which clinical data were available (September 2012). Disease-
specific survival was calculated comparing samples with an amplification of a candidate 
gene against those without. In each dataset, patients without a CNA call for a specific gene 
were excluded from the survival analysis. For each analysis, significance was calculated by 
a log rank test and the hazard ratio (HR) is reported. To compare the effect of candidate 
gene copy number status on common prognostic markers including proliferation (PAM50 
proliferation signature), molecular subtype (PAM50), tumor stage, node status, ER status, 
HER2 status, or age at diagnosis, a multivariate Cox model was used.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Patterns of genomic signature pathway activity in breast cancer
(A) Patterns of pathway activity (n=52) were determined for each sample in the published 
TCGA Breast Cancer cohort (n=476). Expression signature scores (y-axis) are median 
centered and clustered by complete linkage hierarchical clustering. (B) An ANOVA 
(P<0.0001) for all signatures according to PAM50 subtype followed by a Tukey test for 
pair-wise comparison demonstrates statistically significant differences in the levels of 
pathway expression between molecular subtypes. Box color indicates level of significance 
between subtypes as indicated by the legend.
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Figure 2. Identification of genomic pathway-specific copy number alterations
(A) Schematic outlining strategy used to identify CNA associated with pathway activity. (B) 
For each signature, significant copy number gains and losses were calculated. The plot 
identifies those genes that had a positive Spearman rank correlation and have increased 
amplification frequency (q<0.01) (red), or that have a negative Spearman rank correlation 
and show an increased frequency of copy number losses in the top scoring (top quartile) 
samples with pathway activity (q<0.01) (blue). (C–E) A Spearman rank correlation was used 
to identify genes positively (black line) or negatively (dark blue) associated with pathway 
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activity and a Fisher’s exact test was used to compare the frequency of copy number gains 
(red) or losses (light blue) for the (C) Her2 Amp (D) Her1-C2 signature, and (E) RB-LOH 
signature. Yellow arrows indicate known pathway drivers with q<0.01 for each analysis; 
black arrow indicates q<0.01 for a single analysis. In each figure, chromosomal boundaries 
are indicated by vertical black lines.
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Figure 3. Identification of DNA copy number alterations in highly proliferative breast tumors
(A) Distribution of proliferation scores across all tumors and (B) by subtype. (B) Box and 
whisker plots indicate median score and the upper and lower quartile. Basal-like (n=88), 
HER2E (n=55), LumA (n=214) and LumB (n=119). (C) Highly proliferative tumors (top 
quartile) are comprised of Basal-like (49.6%), LumB (33.6%) and HER2E (16.8%). (D) 
Highly proliferative luminal tumors are restricted to LumB (68.0%) and HER2E (32.0%) 
samples. (E) Frequency of CNA in highly proliferative (black line) and all other samples 
(gray line). (F) Statistical analyses of CNA: positive correlation (black) and negative (dark 
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blue) Spearman rank correlation and Fisher’s exact test of amplification (red) or deletion 
(light blue) frequency. (G) Frequency of CNA in highly proliferative luminal tumors; color 
key same as (E). (H) Statistical analyses of CNA in proliferative luminal tumors; color key 
same as (F). Chromosomal boundaries in (E–H) are defined by vertical black lines.
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Figure 4. Identification of genomic pathway-associated essential genes in cell lines
(A) Schematic outlining strategy used to identify pathway-specific genetic dependencies. 
(B) A panel of 27 breast cancer cell lines with both expression data and data from a genome-
wide RNAi screen was used to identify pathway-specific genes required for cell viability 
using a negative Spearman rank correlation (-log10 P-values plotted); significant genes 
(P<0.05) are shown according to chromosome location. Vertical black lines indicate 
chromosomal boundaries. (C) ESR1 (D) ERBB2 and (E) STAT1 or JAK3 shRNA levels are 
inversely associated with the ER, Her2 or Stat1pathway scores.
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Figure 5. Identification of essential genes amplified in highly proliferative luminal tumors
(A) Schematic outlining the integrated genomic strategy to identify essential genes amplified 
in highly proliferative luminal breast tumors. (B) Identification of 21 genes in amplified loci 
that are unique to highly proliferative luminal tumors and are specifically required for 
luminal cell line proliferation in vitro. mRNA expression of genes in red and blue were 
significantly associated with CNA status, with the subset highlighted in red being further 
validated in the METABRIC dataset; genes in black do not show a significant mRNA-DNA 
correlation. Candidate genes demarcated by (*) are located at cusp of a CNA segment and 
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were originally excluded, but mentioned here. Genes identified by (#) were not included on 
mRNA expression microarrays, and the correlation between DNA and mRNA expression 
was not assessed.
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Figure 6. Candidate gene amplification correlates with a poor prognosis
Amplification of (A) FGD5 (NAMP=51, NNoAMP=337), (B) METTL6 (NAMP=51, 
NNoAMP=337), (C) DTX3 (NAMP=71, NNoAMP=317) and (D) MRSP23 (NAMP=127, 
NNoAMP=261) correlated with poor disease-specific outcome in the luminal breast cancer 
patients in the TCGA dataset (n=388) while (E) CPT1A (NAMP=111, NNoAMP=277) 
amplification had no effect on prognosis. Consistent results were observed in the 
METABRIC dataset (n=1,333) for (F) FGD5 (NAMP=42, NNoAMP=1,218), (G) METTL6 
(NAMP=44, NNoAMP=1,278), (H) DTX3 (NAMP=67, NNoAMP=1,266), (I) MRPS23 
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(NAMP=266, NNoAMP=1,062) and (J) CPT1A (NAMP=241, NNoAMP=1,029). Samples in the 
METABRIC dataset missing CNA calls were excluded. For each analysis, P-value 
determined by log-rank test and Hazard Ratio (HR) are reported.
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